Emerging Data on Firmonertinib for PACC Mutations in NSCLC

Panelists discuss how firmonertinib, a fourth-generation EGFR tyrosine kinase inhibitor, has demonstrated promising properties such as strong central nervous system penetration and broad activity against classical and uncommon EGFR mutations.

Panelists discuss how it is already approved in China for EGFR-mutated non–small cell lung cancer (NSCLC) and is under global investigation in multiple settings, including first line, second line, and adjuvant therapy.

Panelists discuss how these studies may redefine the treatment landscape by offering a potentially more effective and better-tolerated option for patients with PACC-driven NSCLC.